Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Sustained Overall Survival Benefit with Lenalidomide Plus Dexamethasone Versus No Treatment in Patients with Smoldering Myeloma at High Risk of Progression to Myeloma: Long Term Analysis

Maria-Victoria Mateos, MD PhD, Miguel-T Hernandez, Pilar Giraldo, MD PhD, Javier De La Rubia, Felipe De Arriba, Lucia Lopez-Corral, Laura Rosiñol, Bruno Paiva, PhD, Luis Palomera, MD PhD, Joan Bargay, MD, Albert Oriol, Felipe Prosper, MD, Javier Lopez, Sr., MD PhD, Jose-María Arguiñano, Nuria Quintana, Jose Luis Garcia, Joan Bladé, Juan José Lahuerta, MD PhD, Jesus San Miguel, MD PhD

Blood (2016) 128 (22): 3308.

https://doi.org/10.1182/blood.V128.22.3308.3308

Published: 2016

Journal Articles

Long Term Follow-up on the Tretament of High Risk Smoldering Myeloma with Lenalidomide Plus Low Dose Dex (Rd) (phase III spanish trial): Persistent Benefit in Overall Survival

Maria-Victoria Mateos, MD PhD, Miguel T Hernandez, MD, Pilar Giraldo, MD PhD, Javier De La Rubia, Felipe de Arriba, Lucía López-Corral, MD PhD, Laura Rosiñol, MD PhD, Bruno Paiva, PhD, Luis Palomera, Joan Bargay, MD, Albert Oriol, MD, Felipe Prosper, MD, Javier López, Eduardo Olavarría, MD, Nuria Quintana, Jose Luis García, Joan Blade, Juan José Lahuerta, MD PhD, Jesus F. San Miguel

Blood (2014) 124 (21): 3465.

https://doi.org/10.1182/blood.V124.21.3465.3465

Published: 2014

Journal Articles

Smoldering Multiple Myeloma (SMM) At High-Risk of Progression to Symptomatic Disease: A Phase III, Randomized, Multicenter Trial Based On Lenalidomide-Dexamethasone (Len-Dex) As Induction Therapy Followed by Maintenance Therapy with Len Alone Vs No Treatment

Blood (2011) 118 (21): 991.

https://doi.org/10.1182/blood.V118.21.991.991

Published: 2011

Journal Articles

Reversibility of the Resistance to Lenalidomide and Pomalidomide and Absence of Cross-Resistance in a Murine Model of MM

Enrique M Ocio, Diego Fernández-Lázaro, Laura San-Segundo, Lorena González-Méndez, Montserrat Martín-Sánchez, Mercedes Garayoa, Teresa Paíno, Antonio Garcia-Gomez, Norma C. Gutierrez, Manuel Delgado, Juan C. Montero, Nuria Quintana, Jose Luis García, Atanasio Pandiella, Jesús F. San Miguel, MD, PhD

Blood (2011) 118 (21): 134.

https://doi.org/10.1182/blood.V118.21.134.134

Published: 2011

Journal Articles

Smoldering Multiple Myeloma (SMM) at High-Risk of Progression to Symptomatic Disease: A Phase III, Randomized, Multicenter Trial Based On Lenalidomide-Dexamethasone (Len-Dex) as Induction Therapy Followed by Maintenance Therapy with Len Alone Vs No Treatment

Blood (2010) 116 (21): 1935.

https://doi.org/10.1182/blood.V116.21.1935.1935

Published: 2010

Journal Articles

Multicenter, Randomized, Open-Label, Phase III Trial of Lenalidomide-Dexamethasone (Len/dex) Vs Therapeutic Abstention in Smoldering Multiple Myeloma at High Risk of Progression to Symptomatic MM: Results of the First Interim Analysis.

Blood (2009) 114 (22): 614.

https://doi.org/10.1182/blood.V114.22.614.614

Published: 2009

NARROW

Sustained Overall Survival Benefit with Lenalidomide Plus Dexamethasone Versus No Treatment in Patients with Smoldering Myeloma at High Risk of Progression to Myeloma: Long Term Analysis

Long Term Follow-up on the Tretament of High Risk Smoldering Myeloma with Lenalidomide Plus Low Dose Dex (Rd) (phase III spanish trial): Persistent Benefit in Overall Survival

Smoldering Multiple Myeloma (SMM) At High-Risk of Progression to Symptomatic Disease: A Phase III, Randomized, Multicenter Trial Based On Lenalidomide-Dexamethasone (Len-Dex) As Induction Therapy Followed by Maintenance Therapy with Len Alone Vs No Treatment

Reversibility of the Resistance to Lenalidomide and Pomalidomide and Absence of Cross-Resistance in a Murine Model of MM

Smoldering Multiple Myeloma (SMM) at High-Risk of Progression to Symptomatic Disease: A Phase III, Randomized, Multicenter Trial Based On Lenalidomide-Dexamethasone (Len-Dex) as Induction Therapy Followed by Maintenance Therapy with Len Alone Vs No Treatment

Multicenter, Randomized, Open-Label, Phase III Trial of Lenalidomide-Dexamethasone (Len/dex) Vs Therapeutic Abstention in Smoldering Multiple Myeloma at High Risk of Progression to Symptomatic MM: Results of the First Interim Analysis.

Email alerts

ASH Publications

American Society of Hematology

Sustained Overall Survival Benefit with Lenalidomide Plus Dexamethasone Versus No Treatment in Patients with Smoldering Myeloma at High Risk of Progression to Myeloma: Long Term Analysis

Long Term Follow-up on the Tretament of High Risk Smoldering Myeloma with Lenalidomide Plus Low Dose Dex (Rd) (phase III spanish trial): Persistent Benefit in Overall Survival

Smoldering Multiple Myeloma (SMM) At High-Risk of Progression to Symptomatic Disease: A Phase III, Randomized, Multicenter Trial Based On Lenalidomide-Dexamethasone (Len-Dex) As Induction Therapy Followed by Maintenance Therapy with Len Alone Vs No Treatment

Reversibility of the Resistance to Lenalidomide and Pomalidomide and Absence of Cross-Resistance in a Murine Model of MM

Smoldering Multiple Myeloma (SMM) at High-Risk of Progression to Symptomatic Disease: A Phase III, Randomized, Multicenter Trial Based On Lenalidomide-Dexamethasone (Len-Dex) as Induction Therapy Followed by Maintenance Therapy with Len Alone Vs No Treatment

Multicenter, Randomized, Open-Label, Phase III Trial of Lenalidomide-Dexamethasone (Len/dex) Vs Therapeutic Abstention in Smoldering Multiple Myeloma at High Risk of Progression to Symptomatic MM: Results of the First Interim Analysis.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only